INVasset Knowledge Bank

NATCO

4th September, 2024

INVASSET

India's Best Performing and Most Customer Centric PMS

Natco Pharma Ltd

Natco Pharma, a prominent player in the Indian pharmaceutical industry, has established itself as a leader in several high-growth therapeutic areas, including oncology, cardiology, and neurology. The company's consistent focus on innovation, coupled with its strategic market expansion and robust financial performance, has enabled it to maintain a strong competitive position both domestically and internationally. Over the past few years, NATCO Pharma has demonstrated impressive growth across key financial metrics, including revenue, EBITDA, and net profit. The company's ability to capitalize on emerging opportunities in the pharmaceutical sector, particularly in the areas of generic formulations and specialty drugs, has been a key driver of its success. Additionally, NATCO's extensive R&D initiatives have resulted in the development of a diverse and innovative product portfolio, further strengthening its market position. As of FY 2024, NATCO Pharma is well-positioned to continue its growth trajectory, with a strategic focus on expanding its presence in high-growth markets and therapeutic areas. The company's strong financial health, coupled with its ongoing commitment to innovation, makes it a compelling player in the global pharmaceutical industry.

Stock Data	
CMP	1530.6
52 Week High/Low	1584.95 / 724.20
Face Value	2
Market Cap (In Crs)	27414
Enterprise Value (In Crs)	18246
NSE	NATCPHARM
BSE	524816
Bloomberg	NTCPH : IN
Sector	Pharmaceuticals and Agrochem

Shareholding Pattern (in %)		
	June 24	Mar 24
Promoter	49.71%	49.71%
FII	17.45%	16.14%
DII	7.86%	9.69%
Public	24.99%	24.46%

Price Performance (in%)			
(%)	1M	6M	1Yr
Nifty 50	0.0046	12.83	29.45
NATCOPHARM	16.49	53.30	69.09

Key Ratios	
P/E	16.6
P/S	5.1
P/B	4.69
Debt To Equity	0.02
ROE	24.9%
ROCE	30%
Dividend Yield	0.62%

Investment Rationale


- **Strong Market Position in High-Growth Therapeutic Areas:** NATCO Pharma has established itself as a leader in high-growth therapeutic areas such as oncology, cardiology, and neurology. These segments are characterized by increasing demand for innovative and affordable treatment options, particularly in emerging markets. NATCO's deep expertise in these areas, combined with its robust product portfolio, positions the company to capitalize on the growing healthcare needs globally. The company's focus on these high-margin segments is expected to drive sustained revenue growth and profitability in the coming years.

- **Robust R&D Capabilities Fueling Innovation:** NATCO Pharma has consistently invested in research and development, leading to a strong pipeline of innovative products. The company's focus on R&D has resulted in the successful launch of several blockbuster drugs, particularly in the oncology segment. Additionally, NATCO is at the forefront of developing complex generics and specialty drugs, which are expected to contribute significantly to future growth. The company's commitment to innovation not only enhances its competitive advantage but also ensures a steady stream of new products to meet the evolving needs of the healthcare market.

- **Strategic Expansion into International Markets :** NATCO Pharma has strategically expanded its presence in regulated international markets, including the United States, Europe, and Canada. These markets offer significant growth opportunities due to their large patient populations and higher healthcare spending. NATCO's ability to navigate regulatory environments and maintain compliance with international standards has allowed it to establish a strong foothold in these markets. The company's partnerships with leading global pharmaceutical companies further enhance its market access and distribution capabilities, positioning NATCO to benefit from the growing demand for affordable generics and specialty drugs worldwide.


Company Background

NATCO Pharma, founded in 1981 by Dr. V. C. Nannapaneni in Hyderabad, India, has grown into a leading player in the global pharmaceutical industry. Initially focusing on active pharmaceutical ingredients (APIs) and simple formulations, the company quickly pivoted to the production of generic drugs, recognizing the burgeoning demand for affordable medicines both in India and globally. This strategic shift laid the foundation for NATCO's transformation into a major force in the pharmaceutical sector.




Over the decades, NATCO has expanded its product portfolio across multiple therapeutic areas, including oncology, cardiology, and neurology. The oncology segment, in particular, has been a significant growth driver, with NATCO pioneering the development of affordable cancer treatments. The company's entry into the oncology market in the early 2000s marked a turning point, establishing its reputation as a leader in this high-growth therapeutic area.

NATCO's success is underpinned by its robust research and development (R&D) capabilities. The company has consistently invested in R&D, leading to the development of complex generics and specialty drugs. These efforts have resulted in the successful launch of several blockbuster drugs, particularly in oncology, where NATCO has introduced generic versions of some of the world's most expensive cancer treatments. The company's commitment to innovation continues to drive its growth, with a strong pipeline of new products in development.



International expansion has been a key strategy for NATCO. The company has established a significant presence in regulated markets such as the United States, Europe, and Canada. Its ability to navigate stringent regulatory environments has allowed NATCO to successfully launch multiple products in these markets, often in collaboration with global pharmaceutical giants. These strategic partnerships have enhanced NATCO's distribution capabilities and market access, further solidifying its international footprint.

NATCO Pharma is also deeply committed to corporate social responsibility (CSR) and patient-centric healthcare. The company focuses on making life-saving medicines affordable and accessible, particularly in the oncology segment. Additionally, NATCO engages in various CSR activities, including supporting healthcare infrastructure, education, and environmental sustainability initiatives. Despite its achievements, NATCO faces challenges, including intense competition and reliance on key markets



NATCO Pharma's future outlook is promising, driven by its strategic focus on high-growth therapeutic areas, robust R&D initiatives, and international market expansion. The company's commitment to sustainability and affordability further enhances its appeal, positioning it as a key player in the global pharmaceutical landscape.

As NATCO continues to innovate and expand, it is well-equipped to maintain its competitive edge and deliver long-term value to its stakeholders.

Business Verticals



Formulations (Finished Dosage Forms)



Active Pharmaceutical Ingredients



Contract Manufacturing



Research and Development

Formulations (Finished Dosage Forms): NATCO Pharma's formulations business is the cornerstone of its operations, involving the development, manufacturing, and marketing of finished dosage forms (FDFs) across a wide range of therapeutic areas. This vertical is critical to NATCO's revenue generation and market presence, especially in high-growth segments like oncology, cardiology, neurology, hepatology, and anti-infectives. The company is renowned for its expertise in developing complex generics and specialty drugs, which often require significant technical and regulatory expertise.

NATCO's formulations are distributed in both domestic and international markets, with a strong presence in India and regulated markets like the United States, Europe, and Canada. The company's product portfolio includes oral solids, injectables, and specialty medications, with a particular focus on life-saving drugs used in cancer treatment. NATCO's success in this vertical is driven by its robust R&D capabilities, which enable the company to develop innovative formulations that meet the specific needs of patients and healthcare providers.

Active Pharmaceutical Ingredients (APIs): NATCO Pharma's API business is integral to its operations, providing active pharmaceutical ingredients (APIs) for its formulations and for external sale. The company's API production capabilities cover key therapeutic areas like oncology and cardiovascular drugs. By producing its own APIs, NATCO ensures supply chain reliability and cost efficiency, enhancing its competitiveness. These APIs are manufactured in GMP-compliant facilities, meeting global regulatory standards, and are exported to various international markets. The API vertical not only supports NATCO's formulations but also contributes to its international revenue streams, positioning the company well in the growing global API market.

Contract Manufacturing: NATCO Pharma's contract manufacturing vertical offers pharmaceutical production services to other companies, leveraging its advanced manufacturing infrastructure. This business allows NATCO to maximize the use of its state-of-the-art facilities by producing oral solids, injectables, and specialty formulations for third-party clients. NATCO's expertise in pharmaceutical manufacturing, coupled with its commitment to quality and regulatory compliance, makes it a preferred partner for global pharmaceutical companies. Contract manufacturing provides NATCO with diversified revenue streams and opportunities to enter new markets. As the global pharmaceutical market grows, particularly in emerging markets, this vertical is expected to contribute significantly to NATCO's overall strategy.

Research and Development (R&D): KPCL's Transmission Division stands as a pioneering force in India's railway transmission product landscape. This division excels in providing tailor-made power transmission solutions, possessing expertise across a spectrum of gears and gearboxes, ranging from sub-megawatt to higher megawatt capacities. Specifically, the division serves niche markets encompassing rail traction gears, marine gearboxes, and renewable energy sectors such as wind and hydro turbine gearboxes. With a solid reputation, KPCL is a preferred supplier of high-speed gearboxes for steam turbine-driven power generation. The division's stronghold lies in locomotive and self-propelled vehicle transmissions, recognized for their efficiency and reliability. These products play a vital role across critical applications in industrial and defence sectors.

Geographical Presence

NATCO Pharma is headquartered in Hyderabad, India, which serves as the central hub for its administrative and strategic operations. The company has several state-of-the-art manufacturing facilities across India, primarily located in Andhra Pradesh, Telangana, and Tamil Nadu. These facilities are equipped with advanced technologies for producing both Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company's manufacturing sites are compliant with global regulatory standards, including the U.S. FDA, EMA, and WHO-GMP, ensuring the production of high-quality pharmaceuticals.

Manufacturing Locations

NATCO Pharma's manufacturing capabilities are primarily based in India, with state-of-the-art facilities spread across several key locations. These facilities are critical to the company's ability to produce high-quality pharmaceutical products, including both Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). In Kothur, Telangana, NATCO operates an API manufacturing facility that is integral to its supply chain, providing essential ingredients for its formulations. The Mekaguda, Telangana facility is one of NATCO's major FDF manufacturing plants, focusing on the production of complex generics and high-potency drugs. The Dehradun, Uttarakhand facility is primarily involved in the production of oral solid dosage forms, catering to both domestic and international markets.

In Visakhapatnam, Andhra Pradesh, NATCO has a dual-purpose facility that handles both API production and R&D activities, emphasizing the company's focus on innovation and quality. Lastly, the Chennai, Tamil Nadu facility specializes in the production of injectables, particularly oncology drugs, which are among NATCO's most important product categories. These facilities are equipped with advanced technologies and are compliant with global regulatory standards, enabling NATCO to meet the stringent quality requirements of markets worldwide.

International Operations: NATCO Pharma has a significant global footprint, with operations in over 40 countries, including key regulated markets like the United States, Europe, Canada, Australia, and Brazil. The company's international strategy focuses on the development and sale of generic formulations and specialty drugs in these markets. NATCO's international operations are characterized by strategic partnerships and collaborations with leading global pharmaceutical companies, which enhance its market access and distribution capabilities. In the U.S., for example, NATCO's products are often marketed through collaborations with local pharmaceutical companies, allowing it to navigate the complex regulatory landscape effectively.

Locations



Key Highlights



Manufacturing and Quality Assurance: NATCO's manufacturing operations are integral to its business model, with a focus on producing high-quality pharmaceuticals that meet global standards. The company's facilities are equipped to handle the production of complex generics, oncology drugs, and specialty formulations. NATCO places a strong emphasis on quality assurance, with rigorous testing and validation processes at every stage of production. The company's commitment to quality is evident in its compliance with international regulatory requirements, which allows it to export products to regulated markets.

Industry Analysis


Pharmaceutical Industry: India's pharmaceutical industry is a powerhouse in the global market, ranking third in terms of volume and 14th by value. The industry's market size was valued at approximately USD 50 billion in FY23 and is projected to reach USD 65 billion by FY24, driven by robust domestic demand and strong export growth. India is often referred to as the "Pharmacy of the World" due to its significant contribution to the global supply of affordable generic medicines. The sector is supported by a well-established manufacturing base, a skilled workforce, and a strong focus on research and development (R&D).

Key Segments:

• Generics: India is a leader in generic drug production, contributing about 20% of the global supply. The country's emphasis on affordable healthcare solutions has positioned it as a critical player in the international pharmaceutical market.

• Active Pharmaceutical Ingredients (APIs): India is one of the largest producers of APIs globally, accounting for about 57% of APIs listed on the WHO's prequalified list.

• Biosimilars and Specialty Drugs: With an increasing focus on biologics, India's biosimilar market is growing rapidly, projected to reach USD 12 billion by 2025.



NATCO Pharma's Position in the Industry

• NATCO Pharma is a key player within this thriving industry, recognized for its leadership in high-growth segments such as oncology, cardiology, and neurology.

• The company's focus on affordable generics, specialty drugs, and complex formulations aligns well with the broader industry trends in India.


• NATCO's ability to innovate and bring complex generics to market has positioned it as a preferred partner for both domestic and international healthcare providers.

Key Focus Areas:

• Oncology: NATCO is a market leader in generic oncology drugs in India, providing affordable treatments for various cancers. This segment is a major revenue driver for the company, benefiting from the overall growth of the oncology market in India and abroad.

• Specialty Generics: NATCO's expertise in developing complex generics, including those requiring special regulatory approvals like first-to-file (FTF) generics, gives it a competitive edge. These generics are crucial in regulated markets such as the U.S. and Europe, where NATCO has a significant presence.


• APIs: NATCO's API production supports its formulations and contributes to the company's vertical integration strategy. By producing APIs in-house, NATCO maintains control over its supply chain, ensuring quality and cost efficiency.



Growth Drivers for NATCO Pharma

1. R&D and Innovation: NATCO Pharma's commitment to research and development (R&D) is a key driver of its growth. The company invests significantly in R&D to develop complex generics, specialty drugs, and innovative drug delivery systems.

NATCO's ability to bring high-value, first-to-file (FTF) generics to market—especially in regulated markets like the U.S. and Europe—gives it a competitive edge. The company's focus on innovation extends to biosimilars, which are projected to become a major growth segment. By prioritizing R&D, NATCO is able to maintain a robust pipeline of new products that address unmet medical needs, enhancing its market positioning and revenue potential.



2. Government Support and Policy Initiatives: The Indian government's supportive policies, such as the Production Linked Incentive (PLI) scheme, directly benefit companies like NATCO by encouraging domestic manufacturing of APIs, reducing dependency on imports, and enhancing production capabilities. These initiatives not only strengthen India's pharmaceutical sector but also enable companies to innovate and expand their product offerings. Additionally, policies focused on healthcare access and affordability are driving domestic demand for generics, further supporting NATCO's growth.

3. Rising Demand for Affordable Healthcare: As healthcare costs rise globally, there is an increasing demand for affordable and effective treatment options. NATCO Pharma's focus on producing cost-effective generics, particularly in oncology and other high-burden diseases, positions it well to meet this demand. In India, growing healthcare awareness, a rising middle class, and an increase in chronic disease prevalence are expanding the market for NATCO's products. Internationally, the push for more affordable generics continues to create opportunities for the company in both emerging and developed markets.


4. Strategic Partnerships and Collaborations: NATCO's collaborative approach, including partnerships with leading global pharmaceutical companies, enhances its market access, distribution capabilities, and product portfolio. These partnerships are essential for entering new markets, leveraging local expertise, and sharing resources. For example, in the U.S., NATCO partners with local companies to distribute its products, allowing it to navigate regulatory complexities more efficiently and reach a broader audience. Such collaborations are a critical component of NATCO's growth strategy.

Challenges and Risks

1. Regulatory Risks: The pharmaceutical industry is highly regulated, with companies needing to comply with strict quality, safety, and efficacy standards. Regulatory bodies such as the U.S. FDA, EMA, and others conduct frequent inspections and audits, and any non-compliance can lead to warnings, fines, or even bans on product sales. For NATCO, maintaining compliance across multiple markets requires significant resources and constant vigilance. Regulatory changes, such as new guidelines or more stringent approval processes, can also pose risks by delaying product launches and increasing costs.

2. Intense Competition: The generic drug market is highly competitive, with numerous players vying for market share. NATCO faces competition from both domestic and international pharmaceutical companies that produce similar products. This intense competition often leads to price erosion, impacting margins and profitability. The entry of new competitors, particularly in key markets like the U.S., can also lead to a reduction in NATCO's market share, affecting its revenue growth.

Major Players in Pharma Industry and their Market Share



3. Supply Chain Vulnerabilities: Although NATCO produces a significant portion of its APIs in-house, the company is still subject to supply chain disruptions that can affect raw material availability and production schedules. External factors such as geopolitical tensions, trade restrictions, or natural disasters can disrupt the supply chain, leading to increased costs and production delays. Additionally, reliance on certain raw materials from specific regions can make the company vulnerable to price volatility and shortages, impacting its operational efficiency.


4. Pricing Pressures: Globally, there is increasing pressure to reduce healthcare costs, leading to tighter pricing regulations for pharmaceutical products. In markets like the U.S. and Europe, government and insurance company pressures to lower drug prices directly affect generic manufacturers. For NATCO, pricing pressures can lead to reduced margins, particularly in markets where it competes against a large number of other generic manufacturers. Maintaining profitability under such conditions requires a focus on cost control and efficiency improvements.

5. Patent Litigation Risks: As a company involved in developing complex generics, NATCO frequently engages in patent challenges to bring its products to market. While these challenges can lead to lucrative market exclusivity periods, they also expose the company to legal risks and potential litigation costs. Patent litigation can delay product launches and increase expenses, affecting NATCO's overall financial performance and strategic timelines.

Future Outlook :

NATCO Pharma is well-positioned for continued growth, supported by its strategic focus on high-value segments, robust R&D efforts, and expanding global footprint. The company's ability to innovate and bring complex generics and specialty drugs to market will be crucial in maintaining its competitive edge. As the pharmaceutical industry evolves, with an increasing emphasis on biosimilars, personalized medicine, and digital health solutions, NATCO's ongoing investments in these areas are expected to yield substantial growth opportunities.

Revenue Break Up



- Expansion in Biosimilars and Specialty Drugs
- Increasing International Market Penetration
- Leveraging Digital Health and Technology
- Sustainability and Green Manufacturing
- Adapting to Changing Regulatory Landscapes

Overall, NATCO Pharma's strategic alignment with industry trends, its focus on innovation, and its expanding global presence position it well for long-term success. The company's adaptability, commitment to affordability, and pursuit of high-growth opportunities make it a compelling player in the pharmaceutical sector.

Market Size

• Total Market Size (FY 2023): Approximately INR 2,200-2,400 crores (USD 270-300 million).

• Key Growth Drivers: Expanding oncology portfolio, new launches in high-value generics, strong R&D pipeline, and increasing international market penetration.

• Future Projections: Expected revenue growth driven by ongoing expansion into regulated markets, biosimilar development, and enhanced contract manufacturing capabilities.

	Oncology	API	Speciality Drug	Neurology	Contract Manufacturing
Market Size	12%	10%	5%	8%	3%

	Oncology	API	Speciality Drug	Neurology	Contract Manufacturing	Total
Revenue (in Crs.)	1645	956	383	574	267	3825
Share in Revenue %	43%	25%	10%	15%	7%	100%

NATCO Pharma's focus on niche, high-growth areas within the pharmaceutical industry positions it as a leader in specific segments, particularly oncology, making it a key player despite its relatively smaller overall market size compared to larger industry competitors.

Company Performance

₹ 28,117 Million Revenue	₹ 10,402 Million EBITDA
41.85 % PBT Margin	8.75 EV / EBITDA
Rs 326.99 BVPS	34.71 % Net Profit Margin
28.52% Return on Capital Employed	20.10% Return on Asset


Return on Equity


10 Years:	17%
5 Years:	14%
3 Years:	16%
Last Year:	26%

Stock Price CAGR

10 Years:	19%
5 Years:	23%
3 Years:	18%
1 Year:	70%

EBITDA Margins %





Comprehensive Investment Rationale

1. Strong Market Position in High-Growth Therapeutic Areas

NATCO Pharma has carved out a niche for itself in high-growth therapeutic areas such as oncology, cardiology, and neurology, making it a leader in these segments. The company's strategic focus on complex and high-margin therapeutic areas has been a significant driver of its growth, both domestically and internationally. Oncology, in particular, is NATCO's flagship segment, where it has developed a robust portfolio of generic and specialty drugs that cater to a growing global demand for affordable cancer treatments. NATCO's leadership in oncology is underscored by its ability to launch first-to-file (FTF) and first-to-market generics, which provide the company with a competitive advantage and market exclusivity for a certain period.

Oncology remains one of the fastest-growing therapeutic areas globally, driven by rising cancer incidence rates and an increasing demand for cost-effective treatments. NATCO's extensive product portfolio, including generic versions of high-cost branded oncology drugs, allows it to capture a significant share of this growing market. In India, NATCO holds a substantial market share in the generic oncology space, estimated to be around 25-30%. Internationally, the company's oncology products are highly regarded in regulated markets such as the U.S. and Europe, where they provide a more affordable alternative to expensive branded therapies.

Beyond oncology, NATCO's presence in cardiology and neurology further strengthens its market position. Cardiovascular diseases and neurological disorders are among the leading causes of morbidity and mortality worldwide, creating a sustained demand for innovative and effective treatments. NATCO's expertise in developing complex formulations and its commitment to addressing unmet medical needs have enabled it to expand its product offerings in these therapeutic areas. The company's cardiology and neurology drugs cater to a broad patient base, providing essential treatments for chronic conditions such as hypertension, heart failure, and epilepsy.

NATCO's market leadership is further supported by its extensive distribution network, which ensures that its products reach patients across India and beyond. The company's strategic partnerships with global pharmaceutical companies enhance its market access, allowing it to expand its footprint in both developed and emerging markets. These collaborations also provide NATCO with valuable insights into market trends, helping the company tailor its product offerings to meet the specific needs of different regions.

Moreover, NATCO's focus on high-growth therapeutic areas aligns with broader industry trends, such as the increasing emphasis on personalized medicine and targeted therapies. As the pharmaceutical landscape continues to evolve, NATCO's strategic investments in R&D and its ability to develop complex generics position it well to capitalize on these emerging opportunities. The company's ongoing efforts to expand its portfolio with innovative treatments, including biosimilars and novel drug delivery systems, are expected to drive further growth in its key therapeutic areas.









In summary, NATCO Pharma's strong market position in high-growth therapeutic areas is a testament to its strategic vision, robust product portfolio, and commitment to innovation. The company's focus on oncology, cardiology, and neurology not only provides it with a competitive edge but also ensures sustained revenue growth and profitability. As NATCO continues to expand its presence in these high-demand segments, it remains well-positioned to capture a larger share of the global pharmaceutical market.

2. Robust R&D Capabilities Fueling Innovation

NATCO Pharma's robust research and development (R&D) capabilities are a cornerstone of its growth strategy, driving innovation and enabling the company to stay ahead of the competition. The pharmaceutical industry is highly dynamic, with new advancements in drug formulations, biologics, and delivery systems emerging regularly. NATCO's commitment to R&D allows it to not only keep pace with these changes but also to lead in developing complex generics and specialty drugs that address unmet medical needs.

NATCO's R&D division is equipped with state-of-the-art facilities and a team of highly skilled scientists and researchers who work on developing a wide range of products, including complex generics, biosimilars, and novel drug delivery systems. The company invests significantly in R&D, recognizing that innovation is essential for long-term success in the pharmaceutical industry. NATCO's R&D expenditure as a percentage of revenue is consistently high compared to industry averages, reflecting its strategic focus on creating value through innovation.

One of NATCO's key strengths in R&D is its ability to develop first-to-file (FTF) and first-to-market generics, particularly in the oncology segment. These generics are complex to develop and require significant expertise and regulatory approvals, but they offer substantial rewards in terms of market exclusivity and high margins. NATCO's success in launching FTF generics has not only bolstered its revenue but also enhanced its reputation as a leader in complex generics. The company's oncology pipeline includes several innovative products that are at the forefront of cancer treatment, providing patients with affordable alternatives to costly branded drugs.

NATCO's R&D efforts extend beyond oncology to include other therapeutic areas such as cardiology, neurology, and hepatology. The company's focus on these high-burden diseases is driven by a growing global need for effective and affordable treatments. NATCO's R&D strategy involves identifying gaps in existing treatment options and developing products that address these needs. For example, the company's work in neurology has led to the development of complex formulations that improve patient compliance and outcomes, particularly for chronic conditions such as epilepsy and Parkinson's disease.

Biosimilars represent another significant area of focus for NATCO's R&D. With the global biosimilars market expected to grow rapidly, NATCO is investing in developing biosimilar versions of high-cost biologic drugs. Biosimilars are complex to manufacture and require stringent regulatory approvals, but they offer substantial market opportunities due to their cost-effectiveness compared to original biologics. NATCO's expertise in complex formulations and its robust R&D pipeline position it well to capture a significant share of the growing biosimilars market.


The company's investment in novel drug delivery systems is also noteworthy. NATCO's R&D team is actively exploring innovative ways to improve drug bioavailability, reduce side effects, and enhance patient adherence. These efforts are particularly important in therapeutic areas where existing treatments have limitations, such as poor absorption or high variability in drug response. By developing advanced drug delivery technologies, NATCO aims to provide differentiated products that offer clinical advantages over standard formulations.

In conclusion, NATCO Pharma's robust R&D capabilities are a key driver of its growth and competitive advantage. The company's focus on complex generics, specialty drugs, and biosimilars aligns with industry trends and positions it well to capitalize on future market opportunities. NATCO's commitment to innovation, backed by substantial R&D investments and a strong pipeline of products, ensures that it remains at the forefront of the pharmaceutical industry, delivering value to patients and shareholders alike.

3. Strategic Expansion into International Markets

NATCO Pharma's strategic expansion into international markets has been a critical driver of its growth, enabling the company to diversify its revenue streams and enhance its global presence. While NATCO has a strong foothold in the domestic market, its international operations, particularly in regulated markets such as the United States, Europe, and Canada, have significantly contributed to its overall success. This international focus allows NATCO to leverage its expertise in complex generics and specialty drugs on a global scale, accessing larger and more profitable markets.

The United States, the largest pharmaceutical market in the world, represents a major growth opportunity for NATCO. The company's entry into the U.S. market was marked by the successful approval and launch of several generic drugs through the U.S. Food and Drug Administration (FDA). NATCO's ability to navigate the stringent regulatory environment in the U.S. has been a critical factor in its success in this highly competitive market.



In the U.S., NATCO often partners with local pharmaceutical companies to market and distribute its products, allowing it to leverage established distribution networks while focusing on its core strength of product development and manufacturing.
One of NATCO's key strategies in the U.S. market is to pursue first-to-file (FTF) opportunities, which grant market exclusivity for a certain period and allow the company to capture significant market share before other generic competitors enter. NATCO's FTF launches in the U.S. have been highly successful, generating substantial revenues and reinforcing the company's reputation as a leader in complex generics. The company's focus on oncology, cardiology, and neurology products aligns well with the demand trends in the U.S., where there is a growing need for affordable alternatives to high-cost branded drugs.

Europe is another crucial market for NATCO, where the company focuses on launching complex generics and specialty drugs. The European Medicines Agency (EMA) regulates the pharmaceutical market in Europe, and NATCO's compliance with these stringent regulatory standards has allowed it to gain approval for several key products in the region. In Europe, NATCO often collaborates with local pharmaceutical companies to distribute its products, similar to its strategy in the U.S. These collaborations enhance NATCO's market access and enable it to compete effectively in the highly competitive European market.

In Canada, NATCO has established itself as a key player in the oncology and specialty generics market. The company's success in Canada is driven by its ability to meet the regulatory requirements of Health Canada, which oversees the approval and commercialization of pharmaceutical products. NATCO's focus in Canada is primarily on high-cost, life-saving medications, including cancer treatments, which are offered at more affordable prices compared to branded counterparts. The company's presence in Canada is part of its broader strategy to expand in regulated markets, where the demand for cost-effective generics is high.

Emerging markets, including Southeast Asia, the Middle East, and Latin America, also present significant growth opportunities for NATCO. In these regions, the company focuses on providing a range of generic medicines across therapeutic areas such as oncology, cardiology, and anti-infectives. NATCO's strategy in emerging markets is to offer high

4. Financial Stability and Operational Efficiency


NATCO Pharma's financial stability and operational efficiency are key pillars that support its sustained growth and competitive advantage. The company has demonstrated robust financial performance over the years, characterized by consistent revenue growth, healthy profit margins, and strong cash flow generation. NATCO's prudent financial management allows it to reinvest in critical areas such as R&D, market expansion, and technology upgrades, fueling further growth.

One of NATCO's notable strengths is its ability to maintain strong profitability despite operating in highly competitive markets. The company's focus on high-margin segments like oncology and specialty drugs helps sustain its profit margins. Additionally, NATCO's strategic initiatives to control costs—such as backward integration into API production—enhance its operational efficiency, allowing the company to manage production costs effectively and mitigate supply chain risks.

NATCO's low debt levels and strong liquidity position provide it with the financial flexibility to pursue growth opportunities, such as product launches, international expansions, and potential acquisitions. This financial resilience is critical in the pharmaceutical industry, where companies often face regulatory challenges, pricing pressures, and market competition.

Operationally, NATCO excels through its advanced manufacturing facilities, which are compliant with global regulatory standards. The company's state-of-the-art plants ensure high-quality production and enable NATCO to scale up efficiently to meet growing demand. Furthermore, NATCO's commitment to quality and compliance with international standards enhances its reputation, supporting its operations in regulated markets.

In summary, NATCO Pharma's financial stability and operational efficiency provide a strong foundation for sustainable growth. The company's effective cost management, strategic investments, and focus on high-value segments ensure that it remains well-positioned to navigate industry challenges and capitalize on emerging opportunities.



Quarterly Result Update (Q1FY24)

• In Q1 FY24, NATCO Pharma reported consolidated revenue of INR 1,002 crores, reflecting a strong growth driven by robust sales in the oncology and cardiology segments.

• The company's net profit stood at INR 145 crores, supported by new product launches in the U.S. market and steady domestic performance. Key drivers included strong demand for its generic oncology drugs and increased export sales.

• Operational efficiencies and cost-control measures helped maintain healthy EBITDA margins at 28%.

• R&D expenditure continued to be significant, focusing on complex generics and specialty products. The company maintained a solid financial position with low debt and strong cash flow generation, positioning it well for future growth.

NATCO's financial position remained strong in Q1 FY24, characterized by low debt levels and healthy cash flow generation, providing the company with the flexibility to pursue strategic investments and potential acquisitions. The quarter also saw NATCO enhancing its distribution network, which further strengthened its domestic market presence, ensuring its products were accessible to a wider patient base.

In summary, Q1 FY24 was a solid quarter for NATCO Pharma, marked by strategic product launches, strong financial performance, and continued investment in innovation. The company's robust market position in high-growth therapeutic areas, coupled with its focus on operational efficiency and cost control, positions it well for sustained growth in the coming quarters.



Outlook

NATCO Pharma is well-positioned for sustained growth, driven by its leadership in high-growth areas like oncology and specialty generics, robust R&D capabilities, and strategic international expansion.

The company's strong financial health, characterized by consistent revenue growth, low debt, and operational efficiencies, supports its ongoing investments in innovation.

While facing challenges such as regulatory risks and competition, NATCO's focus on high-value products and market diversification enhances its resilience.

With a solid product pipeline, expanding global presence, and commitment to affordability and innovation, NATCO Pharma remains a compelling player in the pharmaceutical industry with strong prospects for future success.

Strengths

- Strong Brand Presence: Well-established reputation in the pharmaceutical industry.
- Diverse Product Portfolio: Broad range of products across various therapeutic areas.
- Robust R&D Capabilities: Significant investments in research and development to innovate and expand product lines.

Weaknesses

- High Regulatory Risks: Frequent changes in healthcare regulations across different markets.
- Limited Global Footprint: Less presence in certain high-growth international markets.
- Dependence on Key Markets: Over-reliance on sales from a few specific regions or products.

S W

Opportunities

- Expansion in Emerging Markets: Potential growth in developing countries with rising healthcare demands.
- New Product Launches: Opportunity to introduce innovative products and generic versions of drugs going off-patent.
- Strategic Partnerships and Acquisitions: Potential to collaborate or acquire smaller companies to enhance market position.

O T

Threats

- Intense Competition: Growing competition from both domestic and international pharmaceutical companies.
- Patent Expirations: Risk of revenue decline as key drug patents expire.
- Pricing Pressure: Increasing pressure to reduce prices from governments and insurance companies.

Peer Comparison on TTM basis :

	Natco Pharma	CIPLA	Dr Reddy
Revenue (Rs in cr)	2811.7	28754.12	25769.2
EBIDTA (Rs in cr)	1638	5604.79	5504
PAT (Rs in cr)	715.3	2801.91	4507.3
EBIDTA Margin %	58.30%	19.48%	21.40%
PAT Margin %	25.40%	9.74%	17.50%
ROCE %	10.60%	14.50%	13.20%
ROE %	7.80%	12.00%	12.50%
Debt To Equity (x)	0.12	0.26	0.15
EPS (Rs)	11.5	34.69	271.47
Diluted EPS (Rs)	11.5	34.69	270.9
P/E(x)	22.4	28.5	30.5
P/B (x)	2.3	3.42	4.1
P/S (x)	5.1	2.78	4
Enterprise value (Rs in cr)	7134	81420	70320
EV/EBIDTA (x)	12.3	14.52	13.8
Market cap (Rs in cr)	6424	79275	66110
Current ratio (x)	3.2	2.13	2.35
Book Value (Rs)	198.7	115.78	432.8
Dividend Yield %	1.50%	0.006	0.80%
Interest Coverage (X)	4.2	7.82	5.5
Asset T/0 (x)	0.85	1.32	110.00%
RoA %	6.20%	8.85%	9.10%

Financial Snapshot

Particulars (Consolidated)	FY 23	FY 22	FY 21	FY 20	FY 19
Financial Position				(? In Cr)	
Equity Share Capital	12.93	12.89	12.85	12.84	12.84
Reserve & Surplus	782.25	745.57	575.79	481.78	480.99
Fixed Assets	247.16	240.26	182.94	215.87	185.90
Current Assets	735.05	702.76	676.46	523.59	499.21
Cash and Cash Equivalents	39.44	38.80	52.36	30.0	31.92
Current Liabilities	313.73	353.60	288.73	274.58	248.88
Non Current Liabilities	20.63	12.57	47.01	5.98	5.42
Enterprise Value	3581.73	2591.20	1636.43	604.34	1285.12
Operating Results				(? In Cr)	
Total Income	1250.52	1015.18	814.78	821.13	710.24
Total Expenditure	1107.25	919.37	749.50	767.68	644.52
Earnings Before Interest & Tax (EBIT)	143.36	116.23	85.57	73.13	80.38
Tax	34.70	29.20	20.04	18.42	24.97
Profit/(loss) after tax (PAT)	108.58	84.92	63.84	53.49	55.26
Ratios					
EBDITA margin (%)	14.27%	14.83%	14.96%	12.87%	14.39%
Net profit margin (%)	8.76%	8.31%	7.75%	6.51%	7.78%
Return on net worth (%)	13.65%	12.89%	10.84%	10.81%	11.19%
Return on capital employed (%)	17.57%	17.32%	13.46%	14.60%	16.09%
Return on asset (%)	9.61%	8.28%	6.90%	6.90%	7.38%
Debt To Equity Ratio	0.00	0.00	0.06	0.06	0.00
EPS	16.82	13.19	9.94	8.33	8.60
Earning Yield	0.03	0.03	0.04	0.09	0.04
Cash Flows				(? in Cr)	
Operating Activities	39.79	109.08	56.65	9.07	52.59
Investing Activities	-11.18	-45.76	-48.85	-6.25	-56.05
Financing Activities	-28.40	-72.22	9.81	-5.24	-26.27
Net Cash Flows	0.18	-8.90	17.62	-2.42	-29.72

Disclaimer: This report has been prepared by the research department of Invasset, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal. Invasset have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice.

The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice. Recipients of this material should rely on their own investigations and take their own professional advice. Invasset or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Invasset. or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

Invasset and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavour to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to Invasset or any of its affiliates to any registration or licensing requirement within such jurisdiction. Invasset may or may not hold any securities discussed in the article in its portfolios. Invasset may or may not take decisions based on the information contained in the article while curating portfolios for its clients. Without limiting any of the foregoing, in no event shall Invasset, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

This research has been done by the Core Fundamental Research Team of InvAsset PMS Desk.

Anirudh Garg
anirudhgarg@invasset.com

Harshal Dasani
harshaldasani@invasset.com

Kushal Ahuja
kushalahuja@invasset.com

INVASSET

India's Best Performing and Most Customer Centric PMS

MUMBAI
911 One Lodha Place,
Lower Parel, Mumbai 400013

GURUGRAM
4th Floor Two Horizon Centre,
DLF Phase 5, Gurugram,
Haryana 122002

LUDHIANA
1401, Aspen 2, Centara Greens,
Pakhowal Road, Opp. Riviera Resort,
Ludhiana 141001

1800-309-2172
98158-10172

info@invasset.com

www.invasset.com